Inhibrx, Inc.

Inhibex, Inc.

Kyle S Jones

Brendan P Eckelman

John C Timmer

Quinn L Deveraux

Amir S Razai

Abrahim Hussain

Katelyn M Willis

William Crago

Bryan Becklund

Rajay A Pandit

Lucas Rascon

Andrew Hollands

Chelsie Macedo

Mike Kaplan

Milton Ma

Peter L Nguy

Florian Sulzmaier

Chelsie Hata

Angelica N Sanabria

Jacob Gano

Mark Lappe

Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.

OX40-binding polypeptides and uses thereof

The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.

Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells

Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.

CD123-binding polypeptides and uses thereof

This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.

PDL1-binding proteins

Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.

CD33-binding polypeptides and uses thereof

The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF) and methods of treatment. More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.

Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms

This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.

Multivalent and multispecific OX40-binding fusion proteins

This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.

Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids

Multivalent and multispecific 41BB-binding fusion proteins

Multivalent and multispecific DR5-binding fusion proteins

Multispecific GITR-binding fusion proteins and methods of use thereof

This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.

Growing community of inventors

La Jolla, CA, United States of America

Kyle S Jones